The US FDA has approved durvalumab, a programmed death-ligand 1 blocking antibody, to treat adults with limited-stage small cell lung cancer (LS-SCLC) who have no disease progression following concurrent platinum-based chemotherapy and radiation therapy. Durvalumab has been proven to enhance T-cell activation in vitro and reduce tumor size in co-engrafted human tumor and immune cell xenograft mouse models. Clinical evidence The safety and efficacy of durvalumab were evaluated in a clinical trial involving 730 LS-SCLC patients. The drug demonstrated superiority over a placebo in achieving higher overall survival (55.9 vs.
33.4 months) and progression-free survival (16.6 vs. 9.2 months rates. Dosage and administration An intravenous infusion over 60 minutes Weight ≥ 30 kg: 1,500 mg every four weeks. Weight < 30 kg: 20 mg/kg every four weeks Contraindications – None Warnings and…
